Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
- On the day of the patient's scheduled follow-up visit with their oncologist, additional
blood work will be obtained and the patient will fill out questionnaires concerning
their general health and assessing quality of life.
- A separate cardiology visit with a preventative cardiologist will be performed. At
this visit, the patient will undergo a Stress Echocardiogram.
- A Stress Echocardiogram is made up of three parts: Resting echo study, stress test and
repeat echo while the heart is still beating fast.
- A resting echo provides the baseline examination and demonstrates the size and function
of various chambers of the heart.
- The stress test involves exercise using a treadmill or a stationary bike. In patients
who are unable to complete a high level of exercise due to physical limitations, stress
to the heart is provided by a pharmaceutical or chemical stimulation to the heart.
Exercise is started at a slower, warm-up speed and then increased every 3 minutes.
Exercise is abruptly stopped once the patient exceeds 85% of the target rate. EKG
recordings are made every minute of exercise and then again after exercise is stopped.
Blood pressure is recorded at three minute intervals during exercise and then again at
- Immediately after exercise is stopped, the patient will undergo a repeat
- If no cardiac abnormalities are detected, the screening tests will be repeated every 3
years, if the patient is less than 10 years out from their initial treatment. If the
patient is more than 10 years from initial treatment, then the tests will be repeated
at approximately 18 months from the initial screening and once more at the end of the
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To determine the feasibility of a cardiac screening program in patients who are 5 to 10 years our from initial mediastinal irradiation for Hodgkin's disease.
Peter Mauch, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|